Aselizumab

Aselizumab is an immunosuppressive drug which has been investigated for the use in severely injured patients. It binds to CD62L.[1]

Aselizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD62L
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

References
  1. Seekamp A, van Griensven M, Dhondt E, Diefenbeck M, Demeyer I, Vundelinckx G, et al. (October 2004). "The effect of anti-L-selectin (aselizumab) in multiple traumatized patients--results of a phase II clinical trial". Critical Care Medicine. 32 (10): 2021–8. doi:10.1097/01.CCM.0000142396.59236.F3. PMID 15483410. S2CID 21172224.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.